The scopolamine model as a pharmacodynamic marker in early drug development

Psychopharmacology

Volumn 220, Issue 1, 2012, Pages 97-107

  Lenz, Robert A ^a   Baker, Jeffrey D ^a   Locke, Charles ^a   Rueter, Lynne E ^a   Mohler, Eric G ^a   Wesnes, Keith ^b   Abi Saab, Walid ^a,c   Saltarelli, Mario D ^a,d  

^a ABBOTT LABORATORIES   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d SHIRE   (United States)

Author keywords

Attention; CDR system; Cognition; Donepezil; Episodic memory; Pharmacodynamic marker; Working memory

Indexed keywords

BIOLOGICAL MARKER; DONEPEZIL; PLACEBO;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; BLURRED VISION; COGNITIVE DEFECT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; EPISODIC MEMORY; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAZE TEST; MENTAL PERFORMANCE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SOMNOLENCE; SPATIAL MEMORY; THIRST; VOMITING; WORKING MEMORY; XEROSTOMIA;

ADULT; ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; INDANS; MALE; MAZE LEARNING; MEMORY; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NOOTROPIC AGENTS; PIPERIDINES; RATS; RATS, LONG-EVANS; SCOPOLAMINE HYDROBROMIDE; SINGLE-BLIND METHOD; SPECIES SPECIFICITY; TIME FACTORS; YOUNG ADULT;

EID: 84858441600     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2456-4     Document Type: Article

References (21)

1. Anastasi A (1988) Psychological testing, 6th edn. Macmillan, London
2. Aultman JM, Moghaddam B (2001) Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. Psychophar-macology (Berl) 153:353-364 (Pubitemid 32125820)
3. Bannon AW, Curzon P, Gunther KL, Decker MW (1996) Effects of intraseptal injection of 192-IgG-saporin in mature and aged Long-Evans rats. Brain Res 718:25-36 (Pubitemid 26169905)
4. Bontempi B, Whelan KT, Risbrough VB, Lloyd GK, Menzaghi F (2003) Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. Neuropsychopharmacology 28:1235-1246 (Pubitemid 41070893)
5. Buccafusco JJ, Terry AV Jr, Webster SJ, Martin D, Hohnadel EJ, Bouchard KA, Warner SE (2008) The scopolamine-reversal paradigm in rats and monkeys: the importance of computerassisted operant-conditioning memory tasks for screening drug candidates. Psychopharmacology (Berl) 199:481-494 (Pubitemid 351938233)
6. Bymaster FP, Heath I, Hendrix JC, Shannon HE (1993) Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 267:16-24 (Pubitemid 23324983)
7. Decker MW, Curzon P, Brioni JD, Arneric SP (1994) Effects of ABT-418, a novel cholinergic channel ligand, on place learning in septal-lesioned rats. Eur J Pharmacol 261:217-222 (Pubitemid 24263225)
8. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Heal Econ 22:151-185 (Pubitemid 36279392)
9. Dudchenko PA (2004) An overview of the tasks used to test working memory in rodents. Neurosci Biobehav Rev 28:699-709 (Pubitemid 39535867)
10. Ebert U, Siepmann M, Oertel R, Wesnes KA, Kirch W (1998) Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. J Clin Pharmacol 38:720-726 (Pubitemid 28388222)
11. Ebert U, Grossmann M, Oertel R, Gramatte T, Kirch W (2001) Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. J Clin Pharmacol 41:51-60
12. Edgar C, Wesnes K, Zangara A (2004) The effects of donepezil in healthy elderly volunteers on a scopolamine-challenge model of cognition. J Psychopharmacol (Oxf) 18:A51
13. Jones RW, Wesnes KA, Kirby J (1991) Effects of NMDA modulation in scopolamine dementia. Ann N Y Acad Sci 640:241-244
14. Lindner MD, Hogan JB, Hodges DB Jr, Orie AF, Chen P, Corsa JA, Leet JE, Gillman KW, Rose GM, Jones KM, Gribkoff VK (2006) Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping. Psychopharmacology (Berl) 188:629-640 (Pubitemid 46758973)
15. Molchan SE, Mellow AM, Lawlor BA, Weingartner HJ, Cohen RM, Cohen MR, Sunderland T (1990) TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology (Berl) 100:84-89 (Pubitemid 20015676)
16. Rezvani AH, Kholdebarin E, Cauley MC, Dawson E, Levin ED (2008) Attenuation of pharmacologically-induced attentional impairment by methylphenidate in rats. Pharmacol Biochem Behav 92(1):141-146
17. Riedel W, Hogervorst E, Leboux R, Verhey F, van Praag H, Jolles J (1995) Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology (Berl) 122:158-168 (Pubitemid 26019151)
18. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, Donepezil Study Group (1998) Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 158:1021-1031 (Pubitemid 28213580)
19. Snyder PJ, Bednar MM, Cromer JR, Maruff P (2005) Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimers Dement 1:126-135 (Pubitemid 43348841)
20. Wesnes K, Simpson P, Kidd A (1988) An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg s.c. Hum Psychopharmacol Clin Exp 3:27-41
21. Wesnes KA, Ward T, McGinty A, Petrini O (2000) The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl) 152:353-361